Get the Stockscreener App
8.05
6.76%
0.51
After Hours:
8.05
Prothena Corporation Plc stock is traded at $8.05, with a volume of 1.60M.
It is up +6.76% in the last 24 hours and up +25.78% over the past month.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
See More
Previous Close:
$7.54
Open:
$7.6
24h Volume:
1.60M
Relative Volume:
1.00
Market Cap:
$433.33M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-8.05
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
+1.64%
1M Performance:
+25.78%
6M Performance:
-42.04%
1Y Performance:
-59.71%
1-Day Range:
$7.58
$8.17
1-Week Range:
$7.3852
$8.17
52-Week Range:
$4.32
$22.83
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
8.05 | 405.88M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Can trapped investors hope for a rebound in Prothena Corporation plcFree Investment Strategy With Low Risk - Newser
What MACD signals say about Prothena Corporation plcForecast Model for Intraday Buy Signals - Newser
How to escape a deep drawdown in Prothena Corporation plcFree Low Risk High Return Opportunities - Newser
Building trade automation scripts for Prothena Corporation plcBreakout Stock Opportunities with Low Drawdown - Newser
Ranking Prothena Corporation plc among high performing stocks via toolsDividend Strategy Summary With 10-Year Outlook - Newser
Volume spikes in Prothena Corporation plc stock – what they meanFree Safe Entry Stock Watch Suggestions - Newser
How Prothena Corporation plc stock performs during market volatilityLow Exposure Strategy with Sector Analysis - Newser
Trend Reversal Possible in Prothena Corporation plc Charts IndicateSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - BioSpace
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful - Investing.com India
Prothena (PRTA) Surges on Novo Nordisk's Phase 3 Plans for ATTR Amyloidosis Drug - GuruFocus
Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk - TipRanks
Prothena Announces that Novo Nordisk Will Advance Coramitug (For - GuruFocus
Breakthrough: Novo Nordisk Takes Prothena's ATTR Drug to Final Trial Stage with $1.2B Milestone Potential - Stock Titan
Prothena stock price target lowered to $10 at RBC on program discontinuation By Investing.com - Investing.com South Africa
Prothena stock price target lowered to $10 at RBC on program discontinuation - Investing.com Nigeria
PRTA: RBC Capital Maintains Rating, Lowers Price Target | PRTA S - GuruFocus
9 Analysts Assess Prothena Corp: What You Need To Know - 富途牛牛
Prothena’s Losses Grow As Revenue Drops And Programs Wind Down - Finimize
RBC Cuts Price Target on Prothena to $10 From $18, Keeps Sector Perform, Speculative Risk - MarketScreener
Prothena Corp (PRTA) Maintains 'Buy' Rating with $18 Target by C - GuruFocus
JMP reiterates Market Outperform rating on Prothena stock ahead of key data - Investing.com Nigeria
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - BioSpace
Prothena Reports Q2 2025 Financial Results and Pipeline Progress - TipRanks
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Prothena Corporation PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Prothena Corp PLC Reports Q2 2025 Earnings: EPS Loss of $2.34, Revenue at $4.4 Million, Both Missing Estimates - GuruFocus
Published on: 2025-08-04 19:53:20 - beatles.ru
Prothena Reports Second Quarter 2025 Financial Results and Busin - GuruFocus
How does Prothena Corporation plc generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News
What is the risk reward ratio of investing in Prothena Corporation plc stockMaster stock selection with insider knowledge - Jammu Links News
How strong is Prothena Corporation plc company’s balance sheetInvest smarter with daily stock recommendations - Jammu Links News
What is Prothena Corporation plc company’s growth strategyCapitalize on market shifts with expert advice - Jammu Links News
What catalysts could drive Prothena Corporation plc stock higher in 2025Accelerate your capital gains today - Jammu Links News
Prothena Corporation plc Stock Analysis and ForecastBuild a portfolio that outperforms consistently - Jammu Links News
What are the latest earnings results for Prothena Corporation plcDiscover high-impact stocks for your portfolio - Jammu Links News
Is This a Bottoming Phase for Prothena Corporation plcLow Drawdown Real Time Trading Tips Shared - beatles.ru
Key resistance and support levels for Prothena Corporation plcRisk-Managed Strategy Based on Price Analysis - Newser
Tools to assess Prothena Corporation plc’s risk profileMarket Opportunity Tracker for Swing Traders - Newser
How volatile is Prothena Corporation plc stock compared to the marketEntry Signal Planner To Watch Now - jammulinksnews.com
Intraday pattern recognizer results for Prothena Corporation plcFree Fast Entry High Potential Stock Alerts - Newser
How many analysts rate Prothena Corporation plc as a “Buy”Pre Market Recommendation With Low Risk - Jammu Links News
Can technical indicators confirm Prothena Corporation plc’s reversalCommunity Picked Stocks with Trade Insights - Newser
Prothena Secures Leadership with New Executive Agreements - The Globe and Mail
Sector ETF performance correlation with Prothena Corporation plcMarket Entry and Exit Point Tips From Traders - metal.it
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):